Hostname: page-component-5c6d5d7d68-tdptf Total loading time: 0 Render date: 2024-08-08T00:09:59.079Z Has data issue: false hasContentIssue false
  • English
  • Français

Fluoxetine and Selegiline – Lack of Significant Interaction

Published online by Cambridge University Press:  18 September 2015

C.H. Waters
C.H. Waters*
Affiliation:
Division of Movement Disorders, Department of Neurology, University of Southern California, Los Angeles, California
*
Department of Neurology, University of Southern California, 1510 San Pablo Street, Suite 615, Los Angeles, California, USA 90033
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The use of the combination of fluoxetine, an anti-depressant serotonin uptake inhibitor, and selegiline, a monoamine oxidase -B inhibitor, was reviewed in a large population of patients with Parkinson’s disease. All records were reviewed from a Parkinson’s disease clinic to determine how many patients were treated simultaneously with selegiline and fluoxetine. Patient characteristics, duration and dose of treatment, side effects and reasons for discontinuation were noted. Twenty-three patients received both medications at the same time. No additional side effects were noted with the combination therapy that had not already been reported with each medication alone. No serious side effects were found. In this clinic population, fluoxetine and selegiline were used in combination without major side effects, but further observation is warranted.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 21 , Issue 3 , August 1994 , pp. 259 - 261
Copyright
Copyright © Canadian Neurological Sciences Federation 1994

References

1.Wong, DT, Bymaster, FP, Reid, LR, et al. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 1983; 32: 1287–1293.CrossRefGoogle ScholarPubMed
2.Knoll, J: The possible mechanisms of action of (-) deprenyl in Parkinson’s disease. J Neural Transm 1978; 43: 177–198.CrossRefGoogle ScholarPubMed
3.Schulz, R, Antonin, KH, Hoffmann, E, et al. Tyramine kinetic and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989; 46: 528–536.CrossRefGoogle ScholarPubMed
4.Yang, H-Y, Neff, NH.The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 1974; 189: 733–740.Google Scholar
5.Feighner, JP, Boyer, WF, Tyler, DL, Neborsky, RJ.Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–225.Google ScholarPubMed
6.Sternbach, H.Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2: 850–851.CrossRefGoogle ScholarPubMed
7.Peterson, GN.Strategies for fluoxetine-MAOI combination therapy. J Clin Psychiatry 1991; 52: 87.Google ScholarPubMed
8.Suchowersky, O, deVries, J.Possible interactions between deprenyl and prozac. Can J Neurol Sci 1990; 17: 352–353.CrossRefGoogle ScholarPubMed
9.Hughes, PL, Follender, AB.Potential fluoxetine-selegiline interaction. Ann Pharmacotherapy 1992; 26: 1300.Google Scholar
10.Montastruc, JL, Chamontin, B, Senard, JM, et al. Pseudophaechromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet 1993; 341: 555.CrossRefGoogle ScholarPubMed
11.Mayeux, R, Stern, Y, Cote, L, Williams, JBW.Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 1984; 34: 642–646.CrossRefGoogle ScholarPubMed
12.McCance-Katz, , Marek, KL, Price, LH.Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 1992: 42: 1813–1814.CrossRefGoogle ScholarPubMed
13.Hoehn, MM, Yahr, MD.Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.CrossRefGoogle ScholarPubMed
14.Folstein, MF, Folstein, SE, McHugh, PR.“Mini-Mental Status.” A practical method for grading the cognitive state of patients for the physician. J Psychiatr Res 1975; 12: 189–198.CrossRefGoogle Scholar
15.Beasley, CM, Bosomworth, JC, Wernicke, JF.Fluoxetine relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990; 26: 18–24.Google ScholarPubMed
16.Waters, CH.Side effects of selegiline. J Ger Psych Neurol 1992; 1: 31–34.CrossRefGoogle Scholar
17.Bouchard, RH, Pourcher, E, Vincent, P.Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–1353.Google Scholar
18.Jansen Steur, ENH.Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–212.CrossRefGoogle Scholar
19.Cummings, JL.Depression and Parkinson’s Disease: a review. Am J Psychiatry 1992; 149:443–454.Google ScholarPubMed